Review Article

Exosomes as Crucial Players in Pathogenesis of Systemic Lupus Erythematosus

Yue Fei, Qi Liu, Na Peng, Guocan Yang, Ziwei Shen, Pan Hong, Shengjun Wang, Ke Rui, and Dawei Cui

1Shaoxing University School of Medicine, Shaoxing, China
2Department of Hematology, The First Affiliated Hospital of Shaoxing University, Shaoxing, China
3Department of Transfusion, Shaoxing People’s Hospital (Shaoxing Hospital, Zhejiang University School of Medicine), Shaoxing, China
4Department of Rheumatology and Nephrology, The Second People’s Hospital, China Three Gorges University, Yichang, China
5Department of Laboratory Medicine, Affiliated Hospital of Jiangsu University, Zhenjiang, China
6Department of Hematology, Shaoxing People’s Hospital (Shaoxing Hospital, Zhejiang University School of Medicine), Shaoxing, China
7Institute of Laboratory Medicine, Jiangsu Key Laboratory for Laboratory Medicine, Jiangsu University School of Medicine, Zhenjiang, China
8Department of Laboratory Medicine, Affiliated People’s Hospital, Jiangsu University, Zhenjiang, China
9Department of Blood Transfusion, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China

Correspondence should be addressed to Pan Hong; hongpan168@163.com, Shengjun Wang; sjwjs@ujs.edu.cn, Ke Rui; ruike@ujs.edu.cn, and Dawei Cui; daweicui@zju.edu.cn

Received 27 April 2022; Accepted 29 June 2022; Published 20 July 2022

Academic Editor: Lihua Duan

Copyright © 2022 Yue Fei et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Systemic lupus erythematosus (SLE) is a systemic autoimmune disease that affects multiple systems. Its clinical manifestation varies across patients, from skin mucosa to multiorgan damage to severe central nervous system involvement. The exosome has been shown to play an important role in the pathogenesis of autoimmune diseases, including SLE. We review the recent knowledge of exosomes, including their biology, functions, mechanism, and standardized extraction and purification methods in SLE, to highlight potential therapeutic targets for SLE.

1. Introduction

Systemic lupus erythematosus (SLE) is a chronic, systemic, and severe autoimmune disease that affects multiple systems. Patients with SLE have a poor quality of life and high mortality [1] and are more likely to develop comorbidities such as cardiovascular and respiratory diseases, infections, cancers, and osteoporosis [2–5]. Moreover, women are more likely to suffer from SLE than men [6]. Currently, SLE is treated with the application of biological agents, which provide relief and minimize the use of glucocorticoids [7]. SLE patients still require long-term drug-based maintenance, which often has toxic side effects [8]. Long-term use of glucocorticoids can even lead to emotional disorders such as depression in patients [9]. Exosomes as a targeted carrier may reduce drug concentrations in the human body and the accumulation of drug toxicity [10]. Many mechanisms are involved in the etiology and pathogenesis of SLE, but these remain unclear. Exosomes play an important role in innate and adaptive immunity, participate in many physiological and pathological SLE processes, and help maintain immune homeostasis [11]. In recent years, the effect of exosomes in SLE has attracted greater attention. This review introduces exosomes, their immunomodulatory role and
mechanism, and their potential as a new SLE drug target and identifies new opportunities for understanding SLE pathogenesis and biotherapy.

2. Exosome Classification

Extracellular vesicles (EVs) are membrane-derived vesicles surrounded by lipid bilayers in the periphery that are released into the extracellular space by various cell types, mediate intercellular communication, and can be found in various bodily fluids [12]. EVs can be classified based on their release processes as microvesicles (MVs), exosomes, and apoptotic bodies (APBs) [13]. MVs are produced by budding directly from the cell membrane to outside the cell [14], and APBs arise as part of the apoptotic process [15]. Multivesicular bodies (MVBs) are late endosomes that fuse with cell membranes and release their contents as exosomes [16].

EVs are vesicles 30 to 1000 nm or more in size [17]. Exosomes are one type of EV with a size of 30 to 150 nm [18] that contain many transmembrane proteins, including CD9, CD63, and CD81 [19]. Tetraspanin proteins are abundant in the outer membrane and can indirectly control cell interactions through exosomes. They play important roles in regulating physiological processes such as signal transduction, motility, adhesion, cell activation, and tissue differentiation [20]. CD63 is mainly found in MVBs and lysosomes and is closely related to exosome production [21]. Studies have suggested that CD63 is the defining exosome transmembrane protein [22]. The quantification and detection of CD63 on EVs by nanoflow cytometry can determine exosome content in body fluids [23]. CD9 is also present in the endosome system, particularly in MVs, where it is located on the cell surface and facilitates the endocytosis of CD9-positive exosomes [24]. Therefore, CD9 can promote intercellular exosome transport. In addition, studies have suggested that high levels of CD9 on the plasma membrane may be associated with early endosome formation, while CD63 mainly affects the MVB stage [25]. CD9 and CD63 may be associated with exosome formation. The CD29/CD81 complex on the cell surface also promotes intercellular exosome transport [26].

EVs are exosomes surrounded by lipid bilayers that are released by various cells, including macrophages, dendritic cells (DCs), tumor cells, and mesenchymal stem cells (MSCs) [27]. Exosome formation is mainly dependent on the double invagination of the plasma membrane. In the first exosome invagination, the plasma membrane envelopes soluble proteins in the extracellular environment, gradually forming an early-sorting endosome (ESE). The trans-Golgi network and endoplasmic reticulum also facilitate the forming and increasing of ESE content [28, 29]. ESEs can also fuse and eventually mature into late-sorting endosomes (LSEs). With the second exosome invagination, MVBs containing multiple intracavitary vesicles (ILVs) begin to form. The fusion of MVBs with the plasma membrane releases ILVs that become exosomes in the extracellular fluid [30] or are degraded via fusion with lysosomes (Figure 1) [31].

Exosomes are widely distributed in various body fluids [32] and contain adhesion molecules, tetrads, enzymes, scaffolds, nucleic acids, and binding proteins (Figure 2) [33]. Nucleic acids, lipids, and proteins can be transferred...
3. Exosome Function

The functions of exosomes from other cells differ according to the substances they are carrying. For example, macrophage-derived exosomes can overexpress ArfGAP with GTPase domain ankyrin repeat and PH domain 2 (AGAP2) antisense RNA 1 (AGAP2-AS1) or underexpress microRNA-296 (miR-296) to enhance the antiradiotherapy capability of lung cancer cells [43]. Similarly, exosomes derived from M2 macrophages use apolipoprotein E (ApoE), a lipid-transporting lipoprotein found within the brain and periphery, to promote gastric cancer cell migration [44]. In addition, lung adenocarcinoma (LUAD) cells acquire enhanced cell migration, invasion, and angiogenic abilities by absorbing M2 macrophage-derived exosomes [45]. Furthermore, mature DC exosomes can promote osteogenic differentiation and improve bone regeneration by transporting miRNA-335 (miR-335) in thighbone-deficient thymic rats [46]. Moreover, tumor-derived exosomes can promote the polarization of M2 macrophages, while exosomes carrying miRNA-19b-3p (miR-19b-3p) can promote lung cancer metastasis via the Hippo pathway [47]. Finally, exosomes from hepatocellular carcinoma (HCC) cells can promote tumorigenesis by secreting sonic hedgehog (Shh) protein [48], which is closely related to both embryonic development and histogenesis in mammals. These examples highlight how exosome functions are closely related to their origin and contents.

4. Exosome Features

Exosomes are small, can avoid phagocytosis by mononuclear macrophages, and can freely cross the vessel wall and extracellular matrix [49]. Exosomes carry molecules such as CD55 and CD59 on their surface, preventing their damage by complement or coagulation factors [50]. Therefore, CD55 and CD59 can maintain exosome stability. As intercellular transport vesicles, exosomes have remarkable properties, including not stimulating the immune system, avoiding degradation, carrying endogenous bioactive molecules, long persistence, and crossing multiple biological barriers [51, 52]. Small molecule drugs, including functional nucleic acid nanoparticles, may be incorporated into and carried by exosomes [53, 54]. Exosomes have a high degree of biological stability and can stably exist in the blood for an extended time [55]. In addition, the exosome’s specific molecular surface structure can be used to target specific cells [56]. Therefore, exosomes represent a suitable carrier in drug delivery systems.

5. Exosomes as Potential Biomarkers

Studies have found that some miRNAs can be used to diagnose lupus nephritis (LN) based on their levels in urine-borne exosomes of SLE patients [57, 58] and as predictors of early fibrosis [59–61] and the need for LN treatment [62]. In addition, S100 calcium-binding protein A4 (S100A4) protein levels can be used for evaluating LN activity [63]. T cell-derived exosomes contain many molecules, including miRNAs, long noncoding RNAs (lncRNAs), circular RNAs (circRNAs), S100A4, ApoE, and bactericidal permeability-increasing protein (BPI), which can be transported between cells. Therefore, exosomes can be used as novel biomarkers and predictors of SLE progression (Table 1). However, the dearth of highly sensitive exosome detection methods limits their use as potential SLE biomarkers. Cascade signal amplification is one such method that has been proposed based on a biosensor able to detect exosomes at concentrations as low as 44 particles/μL [64]. Alternatively, exosomes can be detected using a human CD63 antibody conjugated to a molecule that enhances the fluorescence of the Alexa Fluor 647 (AF647) dye [65]. These highly sensitive and specific methods for detecting exosomes in the body fluids of patients offer potential diagnostic approaches for SLE biomarkers.
6. Exosome Regulation in SLE

6.1. Negative Regulation of Exosomes in SLE. Exosomes have different effects on recipient cells based on their different sources and substances carried [66]. MSCs are pluripotent stem cells with the ability for self-renewal and multidirectional differentiation. Previous studies have shown that MSCs alleviate LN by inhibiting T follicular helper (Tfh) cell development and subsequent humoral immune activation [67]. MSC-derived exosomes (MSC-Exos) have similar functions to MSCs in treating autoimmune diseases, such as repairing damaged tissue, regulating the immune response, and playing an anti-inflammatory role. While increases in MSC-Exos or their inhibitory function may be beneficial for treating autoimmune diseases, they may improve the immunity of tumors and chronic infectious pathogens. SLE is a chronic autoimmune disease caused by the production of various autoantibodies that can affect and damage multiple organs and systems [68].

The initial stage of SLE is macrophage activation [69]. Macrophages participate in immune and inflammatory processes and acquire different polarized phenotypes in these processes or responses. The polarized macrophage phenotype includes classically activated macrophages (M1) and selectively activated macrophages (M2) [70]. M1 macrophages are closely associated with SLE development and aggression, while M2 macrophages can reduce SLE severity [71]. However, MSC-Exos can inhibit the M1 macrophage polarization, but its mechanism is imprecise. MSC-Exos can increase transfer RNA- (tRNA-) derived small RNA (tsRNA) 21109 (tsRNA-21109) expression, affecting Rap, Ras, Hippo, Wnt, mitogen-activated protein kinase (MAPK), and transforming growth factor β (TGFβ) signaling pathway and inhibiting the immune response, leading to decreased M1 and increased M2 activity [72].

MSC-Exos have immunosuppressive effects on B lymphocytes [73, 74] and regulate the T helper (Th) and regulatory (Treg) cell subgroups to reduce the cytotoxicity and proliferation of cytotoxic T cells and the inflammatory response in SLE patients [75, 76]. It has been reported that MSC-EVs isolated from adipose tissues can improve the structure and function of the kidney and reduce kidney damage and dysfunction by upregulating interleukin 10 (IL-10) expression in a new porcine model of metabolic syndrome (METS) and renal artery stenosis (RAS) [77]. In addition, a study has shown that the direct injection of human bone marrow mesenchymal stem cells into mice with LN helps to control inflammation [78]. However, no studies have yet explored the use of MSC-EVs for treating SLE in mice or humans. Nevertheless, exosomes derived from professional antigen-presenting cells (APCs) can regulate the immune response, and DC-derived EVs (DC-EVs) have been found to have the same effect as DC cells in treating autoimmune diseases [79].

6.2. Positive Regulation of Exosomes in SLE. T cell-derived exosomes have the opposite effect as those from MSCs. These exosomes were found to cause chronic immune activation and produce excessive cytokines and chemokines via the relationship of cell subgroups with lupus type I interferon (IFN) signaling [80]. In addition, exosome delivery of miRNAs promotes IFNα secretion by human plasmacytoid DCs (pDCs) via Toll-like receptor 7 (TLR7) [81]. IFN is one of the most critical cytokines in SLE [82], promoting SLE progression by affecting CD8+ T cells in patients [83]. Increased serum IFN in SLE patients has been found to negatively correlate with component 3 (C3) and 4 (C4) levels [84]. IFN can interact with pDC, T cells, B cells, natural killer (NK) cells, and macrophages to increase their survival and maturation [85]. Inflammatory cytokine and chemokine levels are elevated in SLE patients with elevated IFN levels [80], who are also more likely to develop LN and have a poorer response to immunosuppressive treatment [86]. Therefore, T cell-derived exosomes can promote autoimmunity via cytokines such as IFN.

Studies have suggested that a lack of S100A4 in exosomes derived from highly metastatic HCC (HMH) reduces tumor necrosis factor α (TNFα) expression in the mouse [87, 88], indicating that S100A4 acts to increase TNFα levels. Soluble S100A4 can directly activate the protein kinase B (Akt) signaling pathway to prolong CD8+ T cell survival [89] and promote SLE development [90, 91] through the ability of CD8+ T cells to create autoantibodies and cause organ damage [92]. HMH-derived exosomes were found to have an adverse effect on SLE in patients. Therefore, blocking exosome secretion or inhibiting the production of related pathogenic carriers may be beneficial in treating SLE.

### Table 1: Exosomal biomarkers in SLE.

| Biomarker | Expression | Source | Role and function | References |
|-----------|------------|--------|------------------|------------|
| NEAT1     | High       | Monocytes | Promotes SLE by activating Th2 cells | [117, 118] |
| GAS5      | Low        | PBMCs   | Suppresses SLE by inhibiting CD4+ T cell activation | [119, 120] |
| S100A4    | High       | Plasma  | Prolongs the survival time of CD8+ T cells | [89, 121] |
| BPI       | High       | Exosomes | Inhibits Treg differentiation to promote SLE | [122] |
| ApoE      | High       | PBMCs   | Increase the risk of SLE | [123, 124] |
| miR-124   | Low        | Serum   | Suppresses CD4+ T cells to inhibit SLE | [123, 124] |
| Hsa_circ_0000479 | High | PBMCs | Adjusts SLE progression by regulating the Wnt signaling pathway | [125, 126] |

Note: NEAT1: nuclear paraspeckle assembly transcript 1; GAS5: growth arrest-specific transcript 5; BPI: bactericidal/permeability-increasing protein; ApoE: apolipoprotein E; PBMCs: peripheral blood mononuclear cells.
7. Exosomes in SLE treatment

Exosomes have unique benefits compared to other carriers in SLE treatment. Exosomes have a long half-life, existing for extended periods in the body [93] and can be stored for long periods, either for short periods at 4°C and -20°C or for long periods at -80°C [94]. Exosomes can transport proteins and nucleic acids between cells, protecting them from degradation when they enter cells [95, 96]. Exosomes are small enough to cross biological membranes and even have the capacity to cross biological barriers such as the blood-brain barrier (BBB) and blood-cerebrospinal fluid barrier (BCSFB) [97]. Exosomes can carry different drugs to meet treatment needs [98], prolonging the drug’s half-life and increasing the stability of its release [99]. As drug carriers, exosomes have the innate advantages of prolonged stability, convenient storage, content protection, avoiding immune monitoring, and crossing biological barriers. Therefore, exosomes have the potential to play a more significant role in SLE therapies.

SLE treatment is aimed at alleviating symptoms, preventing damage accumulation, and minimizing drug side effects, improving patients’ long-term prognosis and quality of life. Immunotherapy for patients with autoimmune diseases usually lasts for their whole life. The continuous use of drugs can produce severe adverse reactions and side effects. In recent years, treatment options for SLE patients have been continually updated. Hydroxychloroquine (HCQ) is commonly prescribed for SLE treatment at a dose of no more than 5 mg/kg. Glucocorticoid (GC) doses should be reduced to <7.5 mg during chronic maintenance treatment and eliminated when possible, and the appropriate use of immunomodulators such as methotrexate, azathioprine, and mycophenolate can accelerate the gradual reduction and discontinuation of GC. The addition of belimumab should be considered for persistently active or flaring extrarenal disease. Rituximab (RTX) is recommended for various organ-threatening, refractory conditions [100]. Early treatment can effectively stop disease progression and improve the patients’ long-term quality of life.

Exosome-based drug delivery has been widely reported. The ideal therapeutic strategy is to reduce the required drug concentrations via their targeted delivery, preventing damage accumulation and minimizing side effects. Studies have designed various experimental methods for injecting specific drugs into exosomes and achieving targeted exosome-based therapy. The increasing understanding and development of therapeutic nucleic acids (TNA) [101] enabled plasmid DNA (pDNA) encoding the anti-inflammatory cytokine interleukin 10 (IL-10 pDNA) and the chemotherapeutic drug betamethasone sodium phosphate (BSP) to be incorporated into M2 macrophage-derived exosomes. The results showed that the molecules carried by the exosomes accumulated in large amounts at the target site within the mouse and had beneficial effects [102], indicating that modified exosomes show efficacy in treating autoimmune diseases [103]. However, there were practical problems in this study associated with how to safely manufacture and ensure the quality of exosomes. Nevertheless, delivering drugs to targeted sites via modified exosomes may represent a promising new approach for treating SLE. However, whether it can be safely applied in humans and how to modify exosomes for SLE are complex problems that remain to be solved.

8. Limitations of Exosomes in SLE Treatment

While exosomes have excellent prospects as drug carriers, they also have limitations. The first issue is how to extract and purify the exosomes. Currently, the common method for exosome separation requires ultrafiltration, immunoaffinity, and ultracentrifugation [104]. Differential ultracentrifugation remains the gold standard for exosome separation, but it causes mechanical damage to exosomes and is very time-consuming [105]. The recent development of cutting-edge biosensors for exosome detection and analysis has attracted significant attention because of their speed, convenience, low sample requirements, and high sensitivity and specificity, enabling significant progress in exosome separation and detection [106–108]. Biosensor-based detection and analysis were found to be much better than the traditional methods [109] and may accelerate the study of exosomes to treat SLE. However, due to the unique physical and chemical properties of protein molecules and the lack of exosome classification for transport, it remains difficult to inject them into exosomes. Nevertheless, a new type of engineered exosome has been reported into which therapeutic membrane proteins and soluble protein cargo can be injected [110]. Therefore, resolving these issues has made exosome-based drug delivery to target cells possible. However, the characteristics of exosomes alone were not sufficient to achieve the targeted transport of exogenous cargo to the target tissues. Relevant engineering technologies still under development will be required to improve exosome targeting [111–113].

9. Conclusion

Exosomes play important roles in SLE occurrence and development through various molecular mechanisms that significantly mediate its progression. Through continuous research on exosomes, it may be possible to deliver drugs for long-term use with low side effects for treating SLE. Exosomes have attracted increasing attention from pharmacologists and drug developers as potential drug carriers. Exosomes have been shown to possess substantial benefits in targeted drug and biomolecule delivery for various diseases [114–116], making them excellent candidates for treating SLE and other autoimmune diseases. While exosomes show excellent potential as drug carriers, they also have limitations, including a lack of highly sensitive exosome detection methods and standardized extraction and purification methods and difficulties in actively adding protein molecules into exosomes. Exosome research is in its infancy, and much work remains to be done. Nevertheless, a better understanding of exosome biology and function will increase their applicability as drug carriers for treating human diseases.
Abbreviations

- SLE: Systemic lupus erythematosus
- EVs: Extracellular vesicles
- MV: Microvesicles
- APBs: Apoptotic bodies
- DCs: Dendritic cells
- ESE: Early-sorting endosome
- LSE: Late-sorting endosome
- MVB: Multivesicular body
- ApoE: Apolipoprotein E
- HCC: Hepatocellular carcinoma
- miRNAs: MicroRNAs
- ILV: Intraluminal vesicles
- LN: Lupus nephritis
- MSCs: Mesenchymal stem cells
- AGAP2: ArfGAP with GTPase domain ankyrin repeat
- BPI: Bactericidal permeability-increasing protein
- circRNAs: Circular RNAs
- lncRNAs: Long noncoding RNAs
- APCs: Antigen-presenting cells
- IL-10: Interleukin-10
- IFN: Interferon
- pDCs: Plasmacytoid dendritic cells
- HMH: Highly metastatic hepatocellular carcinoma
- BBB: Blood-brain barrier
- BCSFB: Blood-cerebrospinal fluid barrier
- HCQ: Hydroxychloroquine
- RTX: Rituximab
- GC: Glucocorticoids
- BSP: Betamethasone sodium phosphate
- TNA: Therapeutic nucleic acids
- Tfh: T follicular helper
- Treg cells: T regulatory cells
- METS: Metabolic syndrome
- RAS: Renal artery stenosis
- APBs: Apoptotic bodies
- RAS: Renal artery stenosis
- APCs: Antigen-presenting cells
- IL-10: Interleukin-10
- IFN: Interferon
- Treg cells: T regulatory cells
- pDCs: Plasmacytoid dendritic cells
- HMH: Highly metastatic hepatocellular carcinoma
- BBB: Blood-brain barrier
- BCSFB: Blood-cerebrospinal fluid barrier
- HCQ: Hydroxychloroquine
- GC: Glucocorticoids
- BSP: Betamethasone sodium phosphate
- TNA: Therapeutic nucleic acids
- Tfh: T follicular helper
- MAPK: Mitogen-activated protein kinase
- TGFβ: Transforming growth factor β
- Th: T helper
- TLR7: Toll-like receptor 7
- C3: Component 3
- C4: Component 4
- TNFα: Tumor necrosis factor α
- Akt: Protein kinase B
- tsRNA: Transfer RNA- (tRNA-) derived small RNA
- pDNA: Plasmid DNA.

Data Availability

The data used to support the findings of this study are included within the article.

Conflicts of Interest

The authors declare no competing interests.

Authors’ Contributions

Yue Fei prepared the original draft. Qi Liu prepared the original draft. Na Peng reviewed and edited the paper. Guocan Yang reviewed and edited the paper. Ziwei Shen reviewed and edited the paper. Pan Hong conceptualized the study and reviewed and edited the paper. Shengjun Wang conceptualized the study and reviewed and edited the paper. Ke Rui conceptualized the study and reviewed and edited the paper. Dawei Cui conceptualized the study and reviewed and edited the paper. All authors contributed to the article and approved the submitted version. Yue Fei, Qi Liu, and Na Peng contributed equally to this work.

Acknowledgments

Our manuscript has been edited for proper English language, grammar, punctuation, spelling, and overall style by one highly qualified native English speaking editor at Yijieto-Edit (Certificate Number 20220618184646). The work was supported by the Shaoxing Bureau of Science and Technology (Grant No. 2020A13008) and the National Natural Science Foundation of China (Grant No. 81871709).

References

[1] M. W. Tsang-A-Sjoe and I. E. M. Bultink, “New developments in systemic lupus erythematosus,” Rheumatology, vol. 60, Supplement_6, pp. vi21–vi28, 2021.
[2] L. Song, Y. Wang, J. Zhang, N. Song, X. Xu, and Y. Lu, “The risks of cancer development in systemic lupus erythematosus (SLE) patients: a systematic review and meta-analysis,” Arthritis Research & Therapy, vol. 20, no. 1, p. 270, 2018.
[3] B. Ruaro, A. Casabella, S. Paolino et al., “Traumatic bone score and bone quality in systemic lupus erythematosus patients,” Frontiers in Medicine, vol. 7, article 574842, 2020.
[4] C. F. Kuo, I. J. Chou, F. Rees et al., “Temporal relationships between systemic lupus erythematosus and comorbidities,” Rheumatology, vol. 58, no. 5, pp. 840–848, 2019.
[5] E. Więsik-Szewczyk, E. Rutkowska, I. Kwiecień, M. Korzeniowska, D. Sołdacki, and K. Jahnz-Różyk, “Patients with common variable immunodeficiency complicated by autoimmune phenomena have lymphopenia and reduced Treg, Th17, and NK cells,” Journal of Clinical Medicine, vol. 10, no. 15, p. 3356, 2021.
[6] M. R. W. Barber, C. Drenkard, T. Falasinnu et al., “Global epidemiology of systemic lupus erythematosus,” Nature Reviews Rheumatology, vol. 17, no. 9, pp. 515–532, 2021.
[7] A. Fanouriakis, N. Tziolos, G. Bertsias, and D. T. Boumpas, “Update on the diagnosis and management of systemic lupus erythematosus,” Annals of the Rheumatic Diseases, vol. 80, no. 1, pp. 14–25, 2021.
[8] G. Moroni, G. Frontini, and C. Ponticelli, “When and how is it possible to stop therapy in patients with lupus nephritis: a narrative review,” Clinical Journal of the American Society of Nephrology, vol. 16, no. 12, pp. 1909–1917, 2021.
[9] D. Zucchi, E. Elefante, D. Schiliro et al., “One year in review 2022: systemic lupus erythematosus,” Clinical and Experimental Rheumatology, vol. 40, no. 1, pp. 4–14, 2022.
[10] H. Chen, L. Wang, X. Zeng et al., “Exosomes, a new star for targeted delivery,” Frontiers in Cell and Development Biology, vol. 9, article 751079, 2021.

[11] N. Li, L. Zhao, Y. Wei, V. L. Ea, H. Nian, and R. Wei, “Recent advances of exosomes in immune-mediated eye diseases,” Stem Cell Research & Therapy, vol. 10, no. 1, p. 278, 2019.

[12] E. T. Chivero, R. S. Dagur, E. S. Peebles et al., “Biogenesis, physiological functions and potential applications of extracellular vesicles in substance use disorders,” Cellular and Molecular Life Sciences, vol. 78, no. 11, pp. 4849–4865, 2021.

[13] B. Soltész, G. Buglyó, N. Németh et al., “The role of exosomes in cancer progression,” International Journal of Molecular Sciences, vol. 23, no. 1, p. 8, 2022.

[14] S. Zhu, S. Li, M. Yi, N. Li, and K. Wu, “Roles of microvesicles in tumor progression and clinical applications,” International Journal of Nanomedicine, vol. 16, pp. 7071–7090, 2021.

[15] M. Mathieu, L. Martin-Jaular, G. Lavieu, and C. Théry, “Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication,” Nature Cell Biology, vol. 21, no. 1, pp. 9–17, 2019.

[16] J. Yang, X. Zou, P. A. Iose, and C. Zeng, “Extracellular vesicles: potential impact on cardiovascular diseases,” Advances in Clinical Chemistry, vol. 105, pp. 49–100, 2021.

[17] A. Lo Cicero, P. D. Stahl, and G. Raposo, “Extracellular vesicles shuffling intercellular messages: for good or for bad,” Current Opinion in Cell Biology, vol. 35, pp. 69–77, 2015.

[18] G. N. Alzharni, S. T. Alananzi, S. Y. Alsharif et al., “Exosomes: isolation, characterization, and biomedical applications,” Cell Biology International, vol. 45, no. 9, pp. 1807–1831, 2021.

[19] D. Ter-Ovanesyan, M. Norman, R. Lazarovits et al., “Framework for rapid comparison of extracellular vesicle isolation methods,” eLife, vol. 10, article e70725, 2021.

[20] S. Salunkhe, B. M. Dheeraj, D. Chitkara, and A. Mittal, “Surface functionalization of exosomes for target-specific delivery and in vivo imaging & tracking: strategies and significance,” Journal of Controlled Release, vol. 326, pp. 599–614, 2020.

[21] M. S. Pols and J. Klumperman, “ Trafficking and function of the tetratraspin CD63,” Experimental Cell Research, vol. 315, no. 9, pp. 1584–1592, 2009.

[22] M. Mathieu, N. Névo, M. Jouve et al., “Specificities of exosome versus small ectosome secretion revealed by live intracellular tracking of CD63 and CD9,” Nature Communications, vol. 12, no. 1, p. 4389, 2021.

[23] K. Ekström, R. Crescitelli, H. I. Pétursson, J. Johansson, C. Lässer, and R. O. Bagge, “Characterization of surface markers on extracellular vesicles isolated from lymphatic exudate from patients with breast cancer,” BMC Cancer, vol. 22, no. 1, p. 50, 2022.

[24] A. Lorico, M. Lorico-Rappa, J. Karbanová, D. Corbeil, and G. Pizzorno, “CD9, a tetratraspin target for cancer therapy?,” Experimental Biology and Medicine, vol. 246, no. 9, pp. 1121–1138, 2021.

[25] H. Suárez, Z. Andreu, C. Mazzeo et al., “CD9 inhibition reveals a functional connection of extracellular vesicle secretion with mitophagy in melanoma cells,” Journal of extracellular vesicles, vol. 10, no. 7, article e2082, 2021.

[26] M. Hazawa, K. Tomiyama, A. Saotome-Nakamura et al., “ Radiation increases the cellular uptake of exosomes through CD29/CD81 complex formation,” Biochemical and Biophysical Research Communications, vol. 446, no. 4, pp. 1165–1171, 2014.

[27] M. Li, S. Li, C. du et al., “Exosomes from different cells: characteristics, modifications, and therapeutic applications,” European Journal of Medicinal Chemistry, vol. 207, article 112784, 2020.

[28] G. van Niel, G. D’Angelo, and G. Raposo, “Shedding light on the cell biology of extracellular vesicles,” Nature Reviews. Molecular Cell Biology, vol. 19, no. 4, pp. 213–228, 2018.

[29] S. Gurunathan, M. H. Kang, M. Qasim, K. Khan, and J. H. Kim, “Biogenesis, membrane trafficking, functions, and next generation nanotherapeutics medicine of extracellular vesicles,” International Journal of Nanomedicine, vol. Volume 16, pp. 3357–3383, 2021.

[30] H. Wei, Q. Chen, L. Lin et al., “Regulation of exosome production and cargo sorting,” International Journal of Biological Sciences, vol. 17, no. 1, pp. 163–177, 2021.

[31] R. Kalluri and V. S. LeBlue, “The biology, function, and biomedical applications of exosomes,” Science, vol. 367, no. 6478, p. eaau 6977, 2020.

[32] M. N. Huda, M. Nafiujujanam, I. G. Deagueno et al., “Potential use of exosomes as diagnostic biomarkers and in targeted drug delivery: progress in clinical and preclinical applications,” ACS Biomaterials Science & Engineering, vol. 7, no. 6, pp. 2106–2149, 2021.

[33] D. M. Pegtel and S. J. Gould, “Exosomes,” Annual Review of Biochemistry, vol. 88, no. 1, pp. 487–514, 2019.

[34] S. Sharma, M. K. Masud, Y. V. Kaneti et al., “Extracellular vesicle nanoarchitectonics for novel drug delivery applications,” Small, vol. 17, no. 42, article e2102220, 2021.

[35] M. Waldenmaier, T. Seibold, T. Seufferlein, and T. Eiseler, “Pancreatic cancer small extracellular vesicles (exosomes): a tale of short- and long-distance communication,” Cancers, vol. 13, no. 19, p. 4844, 2021.

[36] A. Ortega, O. Martinez-Arroyo, M. J. Forner, and R. Cortes, “Exosomes as drug delivery systems: endogenous nanovesicles for treatment of systemic lupus erythematosus,” Pharmaceutics, vol. 13, no. 1, p. 3, 2021.

[37] L. Leggio, G. Paternò, S. Vivarelli et al., “Extracellular vesicles as nanotherapeutics for Parkinson’s disease,” Biomolecules, vol. 10, no. 9, p. 1327, 2020.

[38] D. Corbeil, M. F. Santos, J. Karbanová, T. Kurth, G. Rappa, and A. Lorico, “Uptake and fate of extracellular membrane vesicles: nucleoplasmic reticulum-associated late endosomes as a new gate to intercellular communication,” Cell, vol. 9, no. 9, p. 1931, 2020.

[39] C. Tu, Z. du, H. Zhang et al., “Endocytic pathway inhibition attenuates extracellular vesicle-induced reduction of chemosensitivity to bortezomib in multiple myeloma cells,” Theranostics, vol. 11, no. 5, pp. 2364–2380, 2021.

[40] L. Zhang, F. He, L. Gao et al., “Engineering exosome-like nanovesicles derived from Asparagus cochinchinensis can inhibit the proliferation of hepatocellular carcinoma cells with better safety profile,” International Journal of Nanomedicine, vol. Volume 16, pp. 1575–1586, 2021.

[41] S. Wu, M. Luo, Y. V. Nam et al., “Uptake and tumor-suppressive pathways of exosome-associated GKN1 protein in gastric epithelial cells,” Gastric Cancer, vol. 23, no. 5, pp. 848–862, 2020.
[43] F. Zhang, Y. Sang, D. Chen et al., “M2 macrophage-derived exosomal long non-coding RNA AGAP2-AS1 enhances radiotherapy immunity in lung cancer by reducing microRNA-296 and elevating NOTCH2,” *Cell Death & Disease*, vol. 12, no. 5, p. 467, 2021.

[44] P. Zheng, Q. Luo, W. Wang et al., “Tumor-associated macrophages-derived exosomes promote the migration of gastric cancer cells by transfer of functional apolipoprotein E,” *Cell Death & Disease*, vol. 9, no. 4, p. 434, 2018.

[45] K. Wei, Z. Ma, F. Yang et al., “M2 macrophage-derived exosomes promote lung adenocarcinoma progression by delivering miR-942,” *Cancer Letters*, vol. 526, pp. 205–216, 2022.

[46] Z. Cao, Y. Wu, L. Yu et al., “Exosomal miR-335 derived from mature dendritic cells enhanced mesenchymal stem cell-mediated bone regeneration of bone defects in athymic rats,” *Molecular Medicine*, vol. 27, no. 1, p. 20, 2021.

[47] J. Chen, K. Zhang, Y. Zhi et al., “Tumor-derived exosomal miR-19b-3p facilitates M2 macrophage polarization and exosomal LINC00273 secretion to promote lung adenocarcinoma metastasis via Hippo pathway,” *Clinical and Translational Medicine*, vol. 11, no. 9, article e478, 2021.

[48] L. Li, J. Zhao, Q. Zhang et al., “Cancer cell-derived exosomes promote HCC tumorigenesis through Hedgehog pathway,” *Frontiers in Oncology*, vol. 11, article 756205, 2021.

[49] Y. Zhang, J. Bi, J. Huang, Y. Tang, S. Du, and P. Li, “Exosome: a review of its classification, isolation techniques, storage, diagnostic and targeted therapy applications,” *International Journal of Nanomedicine*, vol. Volume 15, pp. 6917–6934, 2020.

[50] A. Clayton, C. L. Harris, J. Court, M. D. Mason, and B. P. Morgan, “Antigen-presenting cell exosomes are protected from complement-mediated lysis by expression of CD55 and CD59,” *European Journal of Immunology*, vol. 33, no. 2, pp. 522–531, 2003.

[51] H. Peng, W. Ji, R. Zhao et al., “Exosome: a significant nanoscale drug delivery carrier,” *Journal of Materials Chemistry B*, vol. 8, no. 34, pp. 7591–7608, 2020.

[52] M. Zhang, X. Zang, M. Wang et al., “Exosome-based nanocarriers as bio-inspired and versatile vehicles for drug delivery: recent advances and challenges,” *Journal of Materials Chemistry B*, vol. 7, no. 15, pp. 2421–2433, 2019.

[53] A. E. Massey, S. Malik, M. Sikander et al., “Clinical implications of exosomes: targeted drug delivery for cancer treatment,” *International Journal of Molecular Sciences*, vol. 22, no. 10, p. 5278, 2021.

[54] S. Nordmeier, W. Ke, K. A. Afonin, and V. Portnoy, “Exosome mediated delivery of functional nucleic acid nanoparticles (NANPs),” *Nanomedicine*, vol. 30, article 102285, 2020.

[55] H. Kim, E. H. Kim, G. Kwak, S. G. Chi, S. H. Kim, and Y. Yang, “Exosomes: cell-derived nanoplatforms for the delivery of cancer therapeutics,” *International Journal of Molecular Sciences*, vol. 22, no. 1, p. 14, 2021.

[56] P. Yang, X. Cao, H. Cai et al., “The exosomes derived from CAR-T cell efficiently target mesothelin and reduce triple-negative breast cancer growth,” *Cellular Immunology*, vol. 360, article 104262, 2021.

[57] R. Mirzaei, F. Zaman, M. Hajibaba et al., “The pathogenic, therapeutic and diagnostic role of exosomal microRNA in the autoimmune diseases,” *Journal of Neuroimmunology*, vol. 358, article 577640, 2021.

[58] R. Vitorino, R. Ferreira, S. Guedes, F. Amado, and V. Thongboonkerd, “What can urinary exosomes tell us?,” *Cellular and Molecular Life Sciences*, vol. 78, no. 7, pp. 3265–3283, 2021.

[59] J. Perez-Hernandez, O. Martinez-Arroyo, A. Ortega et al., “Urine exosomal miR-146a as a marker of albuminuria, activity changes and disease flares in lupus nephritis,” *Journal of Nephrology*, vol. 34, no. 4, pp. 1157–1167, 2021.

[60] C. Solé, T. Moliné, M. Vidal, J. Ordi-Ros, and J. Cortés-Hernández, “An exosomal urinary miRNA signature for early diagnosis of renal fibrosis in lupus nephritis,” *Cell*, vol. 8, no. 8, p. 773, 2019.

[61] B. Y. F. So, D. Y. H. Yap, and T. M. Chan, “MicroRNAs in lupus nephritis-role in disease pathogenesis and clinical applications,” *International Journal of Molecular Sciences*, vol. 22, no. 19, p. 10737, 2021.

[62] E. Garcia-Vives, C. Solé, T. Moliné et al., “The urinary exosomal miRNA expression profile is predictive of clinical response in lupus nephritis,” *International Journal of Molecular Sciences*, vol. 21, no. 4, p. 1372, 2020.

[63] J. L. Turnier, N. Fall, S. Thornton et al., “Urine S100 proteins as potential biomarkers of lupus nephritis activity,” *Arthritis Research & Therapy*, vol. 19, no. 1, p. 242, 2017.

[64] L. Wang, Y. Deng, J. Wei, Y. Huang, Z. Wang, and G. Li, “Spherical nucleic acids-based cascade signal amplification for highly sensitive detection of exosomes,” *Biosensors & Bioelectronics*, vol. 191, article 113465, 2021.

[65] N. Ullah Khan, Z. Muhammad, X. Liu et al., “Ultrasonic detection of exosomes using biofunctionalized gold nanorods on a silver-islard film,” *Nano Letters*, vol. 21, no. 13, pp. 5532–5539, 2021.

[66] J. Zou, H. Peng, and Y. Liu, “The roles of exosomes in immunoregulation and autoimmune thyroid diseases,” *Frontiers in Immunology*, vol. 12, article 757674, 2021.

[67] E. Jang, M. Jeong, S. Kim et al., “Infusion of human bone marrow-derived mesenchymal stem cells alleviates autoimmune nephritis in a lupus model by suppressing follicular helper T-cell development,” *Cell Transplantation*, vol. 25, no. 1, pp. 1–15, 2016.

[68] M. Kiriakidou and C. L. Ching, “Systemic lupus erythematosus,” *Annals of Internal Medicine*, vol. 172, no. 11, p. ITCS1, 2020.

[69] L. J. Shi, Q. Guo, and S. G. Li, “Macrophage activation syndrome as an initial presentation of systemic lupus erythematosus,” *World Journal of Clinical Cases*, vol. 8, no. 11, pp. 2406–2407, 2020.

[70] S. C. Funes, M. Rios, J. Escobar-Vera, and A. M. Kalergis, “Implications of macrophage polarization in autoimmunity,” *Immunology*, vol. 154, no. 2, pp. 186–195, 2018.

[71] F. Li, Y. Yang, X. Zhu, L. Huang, and J. Xu, “Macrophage polarization modulates development of systemic lupus erythematosus,” *Cellular Physiology and Biochemistry*, vol. 37, no. 4, pp. 1279–1288, 2015.

[72] R. Dou, X. Zhang, X. Xu, P. Wang, and B. Yan, “Mesenchymal stem cell exosomal lncRNA-21109 alleviate systemic lupus erythematosus by inhibiting macrophage M1 polarization,” *Molecular Immunology*, vol. 139, pp. 106–114, 2021.

[73] D. Khare, R. Or, I. Resnick, C. Barkatz, O. Almoji-Hazan, and B. Avni, “Mesenchymal stromal cell-derived exosomes affect mRNA expression and function of B-lymphocytes,” *Frontiers in Immunology*, vol. 9, p. 3053, 2018.
S. Hervas-Stubbs, K. Toupet, M. Maumus et al., “Mesenchymal stem cells-derived exosomes are more immunosuppressive than microparticles in inflammatory arthritis,” *Theranostics*, vol. 8, no. 5, pp. 1399–1410, 2018.

K. L. Li, J. Y. Li, G. L. Xie, and X. Y. Ma, “Exosomes released from human bone marrow-derived mesenchymal stem cell attenuate acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation in mice,” *Frontiers in Cell and Development Biology*, vol. 9, article 617589, 2021.

N. Heidari, H. Abbasi-Kenarsari, S. Namaki et al., “Adipose-derived mesenchymal stem cell-secreted exosome alleviates dexamethasone-sodium-induced acute colitis by Treg cell induction and inflammatory cytokine reduction,” *Journal of Cellular Physiology*, vol. 236, no. 8, pp. 5906–5920, 2021.

A. Eirin, X. Y. Zhu, A. S. Puranik et al., “Mesenchymal stem cell-derived extracellular vesicles attenuate kidney inflammation,” *Kidney International*, vol. 92, no. 1, pp. 114–124, 2017.

H. Bukulmez, I. Horkayne-Szakaly, A. Bilgin, T. P. Baker, A. I. Caplan, and O. Y. Jones, “Intrarenal injection of mesenchymal stem cell for treatment of lupus nephritis in mice - a pilot study,” *Lupus*, vol. 30, no. 1, pp. 52–60, 2021.

J. Perez-Hernandez, J. Redon, and R. Cortes, “Extracellular vesicles as therapeutic agents in systemic lupus erythematosus,” *International Journal of Molecular Sciences*, vol. 18, no. 4, p. 717, 2017.

P. López, J. Rodriguez-Carrio, L. Caminal-Montero, and A. Suárez, “Relationship between T-cell exosomes and cellular subsets in SLE according to type I IFN-signaling,” *Frontiers in Medicine*, vol. 7, article 604098, 2020.

V. Salvi, V. Gianello, S. Busatto et al., “Exosome-delivered microRNAs promote IFN-α secretion by human plasmacytoid DCs via TLR7,” *JCI Insight*, vol. 3, no. 10, article e98204, 2018.

M. Postal, J. F. Vivaldo, R. Fernandez-Ruiz, J. L. Paredes, S. Appenzeller, and T. B. Niewold, “Type I interferon in the pathogenesis of systemic lupus erythematosus,” *Current Opinion in Immunology*, vol. 67, pp. 87–94, 2020.

N. Buang, L. Tapeng, V. Gray et al., “Type I interferons affect the metabolic fitness of CD8(+) T cells from patients with systemic lupus erythematosus,” *Nature Communications*, vol. 12, no. 1, p. 1980, 2021.

A. Paradowska-Gorycka, A. Wajda, B. Sypinska et al., “Variety of endosomal TLRs and interferons (IFN-α, IFN-β, IFN-γ) expression profiles in patients with SLE, SSc and MCTD,” *Clinical & Experimental Immunology*, vol. 204, no. 1, pp. 49–63, 2021.

S. Hervas-Stubb, J. L. Perez-Gracia, A. Rouzaut, M. F. Sannamed, A. Le Bon, and I. Meteiro, “Direct effects of type I interferons on cells of the immune system,” *Clinical Cancer Research*, vol. 17, no. 9, pp. 2619–2627, 2011.

Y. Adel and Y. Sadeq, “Impact of IL-34, IFN-α and IFN-λ1 on activity of systemic lupus erythematosus in Egyptian patients,” *Reumatologia*, vol. 58, no. 4, pp. 221–230, 2020.

Y. Wu, H. Li, and Y. Qin, “S100A4 promotes the progression of lipopolysaccharide-induced acute epididymitis in mice,” *Biology of Reproduction*, vol. 102, no. 6, pp. 1213–1224, 2020.

H. Sun, C. Wang, B. Hu et al., “Exosomal S100A4 derived from highly metastatic hepatocellular carcinoma cells promotes metastasis by activating STAT3,” *Signal Transduction and Targeted Therapy*, vol. 6, no. 1, p. 187, 2021.
[105] L. M. Doyle and M. Z. Wang, "Overview of extracellular vesicles, their origin, composition, purpose, and methods for exosome isolation and analysis," Cell, vol. 8, no. 7, p. 727, 2019.

[106] Z. Yu, S. Lin, F. Xia et al., "ExoSD chips for high-purity immunomagnetic separation and high-sensitivity detection of gastric cancer cell-derived exosomes," Biosensors & Bioelectronics, vol. 194, article 113594, 2021.

[107] X. Liu, Q. Wang, J. Chen, X. Chen, and W. Yang, "Ultrasensitive electrochemiluminescence biosensor for the detection of tumor exosomes based on peptide recognition and [email protected]|

[108] L. Y. Zhang, X. Yang, S. B. Wang, H. Chen, H. Y. Pan, and A. Li, Y. Zhao, Y. Li, L. Jiang, Y. Gu, and J. Liu, "Progress in nanomaterials-based optical and electrochemical methods for the assays of exosomes," International Journal of Nanomedicine, vol. 16, pp. 7575–7608, 2021.

[109] J. Wang, X. Huang, J. Xie, Y. Han, Y. Huang, and H. Zhang, "Exosomal analysis advances in biosensor technology," Clinica Chimica Acta, vol. 518, pp. 142–150, 2021.

[110] Q. Cheng, Z. Dai, X. Shi et al., "Expanding the toolbox of exosome-based modulators of cell functions," Biomaterials, vol. 277, article 121129, 2021.

[111] A. Li, Y. Zhao, Y. Li, L. Jiang, Y. Gu, and J. Liu, "Cell-derived biomimetic nanocarriers for targeted cancer therapy: cell membranes and extracellular vesicles," Drug Delivery, vol. 28, no. 1, pp. 1237–1255, 2021.

[112] L. Y. Zhang, X. Yang, S. B. Wang, H. Chen, H. Y. Pan, and Z. M. Hu, "Membrane derived vesicles as biomimetic carriers for targeted drug delivery system," Current Topics in Medicinal Chemistry, vol. 20, no. 27, pp. 2472–2492, 2020.

[113] S. Sil, R. S. Dagur, K. Liao et al., "Strategies for the use of extracellular vesicles for the delivery of therapeutics," Journal of Neuroimmune Pharmacology, vol. 15, no. 3, pp. 422–442, 2020.

[114] H. Ning, H. Chen, J. Deng et al., "Exosomes secreted by FNDC5-BMMSCs protect myocardial infarction by anti-inflammation and macrophage polarization via NF-κB signaling pathway and Nrf 2/HO-1 axis," Stem Cell Research & Therapy, vol. 12, no. 1, p. 519, 2021.

[115] Q. Luo, Y. Shi, Y. Qi, L. Huang, H. Sui, and L. Zhao, "Biomimetic silielinin-macrophage-derived exosomes induce dual inhibition of Aβ aggregation and astrocyte activation to alleviate cognitive impairment in a model of Alzheimer's disease," Materials Science & Engineering. C, Materials for Biological Applications, vol. 129, article 112365, 2021.

[116] A. Shehzad, S. U. Islam, R. Shahzad, S. Khan, and Y. S. Lee, "Extracellular vesicles in cancer diagnostics and therapeutics," Pharmacology & Therapeutics, vol. 223, article 107806, 2021.

[117] F. Zhang, L. Wu, J. Qian et al., "Identification of the long non-coding RNA NEAT1 as a novel inflammatory regulator acting through MAPK pathway in human lupus," Journal of Autoimmunity, vol. 75, pp. 96–104, 2016.

[118] S. Huang, D. Dong, Y. Zhang, Z. Chen, J. Geng, and Y. Zhao, "Long non-coding RNA nuclear paraspeckle assembly transcript 1 promotes activation of T helper 2 cells via inhibiting STAT6 ubiquitination," Human Cell, vol. 34, no. 3, pp. 800–807, 2021.

[119] J. Li, G. C. Wu, T. P. Zhang et al., "Association of long non-coding RNAs expression levels and their gene polymorphisms with systemic lupus erythematosus," Scientific Reports, vol. 7, no. 1, p. 15119, 2017.

[120] Q. Liu, Y. Deng, C. Li et al., "LncRNA GASS suppresses CD4 + T cell activation by upregulating E4BP4 via inhibiting miR-92a-3p in systemic lupus erythematosus," Immunology Letters, vol. 227, pp. 41–47, 2020.

[121] B. Šumová, L. A. Cerezo, L. Szczuková et al., "Circulating S100 proteins effectively discriminate SLE patients from healthy controls: a cross-sectional study," Rheumatology International, vol. 39, no. 3, pp. 469–478, 2019.

[122] H. C. Chuang, M. H. Chen, Y. M. Chen et al., "BPI overexpression suppresses Treg differentiation and induces exosome-mediated inflammation in systemic lupus erythematosus," Theranostics, vol. 11, no. 20, pp. 9953–9966, 2021.

[123] L. J. Song, W. W. Liu, Y. C. Fan et al., "The positive correlations of apolipoprotein E with disease activity and related cytokines in systemic lupus erythematosus," Diagnostic Pathology, vol. 8, no. 1, p. 1, 2013.

[124] M. Tanhapour, A. Mirti, A. Vaisi-Raygani et al., "Synergism between apolipoprotein E 4 allele and paraoxonase (PON1) 55-M allele is associated with risk of systemic lupus erythematosus," Clinical Rheumatology, vol. 37, no. 4, pp. 971–977, 2018.

[125] Q. Luo, L. Zhang, L. Fang et al., "Circular RNAs hsa_circ_0000479 in peripheral blood mononuclear cells as novel biomarkers for systemic lupus erythematosus," Autoimmunity, vol. 53, no. 3, pp. 167–176, 2020.

[126] G. Guo, H. Wang, L. Ye et al., "Hsa_circ_0000479 as a novel diagnostic biomarker of systemic lupus erythematosus," Frontiers in Immunology, vol. 10, p. 2281, 2019.